What is it about?
Four different EGFR targeting cisplatin containing bioconjugates have been evaluated in the F98 EGFR rat glioma model following intracerebral administration by means of convection enhanced delivery. The most therapeutically effective of these employed an EGF peptide as the targeting moiety linked to cisplatin. This resulted in at least doubling of the survival time compared to untreated controls.
Featured Image
Why is it important?
The preliminary results that have been reported suggest that further studies utilizing cisplatin containing EGFR targeting peptides are warranted.
Perspectives
At the present time high grade gliomas are still incurable and new therapeutic approaches are required. The present report described one such approach that warrants further evaluation.
Rolf Barth
Read the Original
This page is a summary of: Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors, OncoTargets and Therapy, May 2016, Dove Medical Press,
DOI: 10.2147/ott.s99242.
You can read the full text:
Contributors
The following have contributed to this page
